These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 23006318)

  • 1. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery.
    Zuccato C; Liber D; Ramos C; Tarditi A; Rigamonti D; Tartari M; Valenza M; Cattaneo E
    Pharmacol Res; 2005 Aug; 52(2):133-9. PubMed ID: 15967378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease.
    Traficante A; Riozzi B; Cannella M; Rampello L; Squitieri F; Battaglia G
    Neuroreport; 2007 Dec; 18(18):1997-2000. PubMed ID: 18007201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease.
    Smith GA; Rocha EM; McLean JR; Hayes MA; Izen SC; Isacson O; Hallett PJ
    Hum Mol Genet; 2014 Sep; 23(17):4510-27. PubMed ID: 24728190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor.
    Baquet ZC; Gorski JA; Jones KR
    J Neurosci; 2004 Apr; 24(17):4250-8. PubMed ID: 15115821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease.
    Anglada-Huguet M; Giralt A; Rué L; Alberch J; Xifró X
    Biochim Biophys Acta; 2016 Jul; 1862(7):1255-66. PubMed ID: 27063456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
    Harada A; Suzuki K; Kimura H
    J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
    Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
    J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.
    Giampà C; Montagna E; Dato C; Melone MA; Bernardi G; Fusco FR
    PLoS One; 2013; 8(5):e64037. PubMed ID: 23700454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
    Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
    Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
    Rite I; Machado A; Cano J; Venero JL
    Exp Neurol; 2005 Mar; 192(1):142-55. PubMed ID: 15698628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
    Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.
    Pineda JR; Canals JM; Bosch M; Adell A; Mengod G; Artigas F; Ernfors P; Alberch J
    J Neurochem; 2005 Jun; 93(5):1057-68. PubMed ID: 15934928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
    Ma Q; Yang J; Li T; Milner TA; Hempstead BL
    Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.
    Canals JM; Pineda JR; Torres-Peraza JF; Bosch M; Martín-Ibañez R; Muñoz MT; Mengod G; Ernfors P; Alberch J
    J Neurosci; 2004 Sep; 24(35):7727-39. PubMed ID: 15342740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
    Wade A; Jacobs P; Morton AJ
    Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment.
    Kells AP; Henry RA; Connor B
    Gene Ther; 2008 Jul; 15(13):966-77. PubMed ID: 18323792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.
    Spires TL; Grote HE; Varshney NK; Cordery PM; van Dellen A; Blakemore C; Hannan AJ
    J Neurosci; 2004 Mar; 24(9):2270-6. PubMed ID: 14999077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.